Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

ClinicalTrials.gov ID: NCT06810544

Public ClinicalTrials.gov record NCT06810544. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Study identification

NCT ID: NCT06810544
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Tango Therapeutics, Inc.; Industry
Enrollment: 191 participants

Conditions and interventions

Conditions

Interventions

TNG456 Drug
abemaciclib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 23, 2025
Primary completion: Mar 30, 2027
Completion: Sep 29, 2027
Last update posted: Apr 12, 2026

2025 – 2027

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Mayo Clinic Scottsdale	Scottsdale	Arizona	85259-5452	Recruiting
University of California, Irvine	Irvine	California	92686	Recruiting
University of California Los Angeles	Los Angeles	California	90995	Recruiting
University of California at San Francisco	San Francisco	California	94143-2202	Recruiting
Sibley Memorial Hospital	Washington D.C.	District of Columbia	20016	Recruiting
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	Recruiting
Northwestern Memorial Hospital	Chicago	Illinois	60611-2908	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Mayo Clinic Cancer Center	Rochester	Minnesota	55905-0001	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	11065	Recruiting
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
University of Utah, Huntsman Cancer Institute	Salt Lake City	Utah	84112-5500	Recruiting
NEXT Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06810544, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06810544 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →